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CLINICAL GUIDELINES
Experts Opinion on the Practical Use of Azathioprine and
6-Mercaptopurine in Inﬂammatory Bowel Disease
Christian Mottet, MD, PhD,*,† Alain M. Schoepfer, MD,† Pascal Juillerat, MD,‡ Jacques Cosnes, MD,§
Florian Froehlich, MD,†,k Vera Kessler-Brondolo, MD,¶ Frank Seibold, MD, PhD,**
Gerhard Rogler, MD, PhD,†† Stephan R. Vavricka, MD,††,‡‡ and Pierre Michetti, MD†,§§
Abstract: The relevance of azathioprine and 6-mercaptopurine therapy in inﬂammatory bowel disease, Crohn’s disease, and ulcerative colitis, has been
challenged in recent publications. In this article, a panel of experts gives advice, based on the relevant literature, on indications and practical use of
azathioprine/6-mercaptopurine, prevention, and management of drug adverse reactions and special situations such as vaccination, pregnancy, and
lactation.
(Inﬂamm Bowel Dis 2016;22:2733–2747)
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T hiopurines are purine antimetabolites that inhibit cell prolif-eration, especially of lymphatic cells. Their use in clinical
medicine dates back more than 60 years, when they were origi-
nally investigated as chemotherapeutics, in particular for the treat-
ment of acute and chronic (lymphatic) leukemia, as well as
non-Hodgkin’s lymphoma. In the 1980s, thiopurines were found
to be effective in Crohn’s disease (CD) and later also in ulcerative
colitis (UC). For more than 20 years, thiopurines prodrugs and
derivatives, i.e., azathioprine (AZA), 6-mercaptopurine (6-MP),
or 6-thioguanine nucleotides (6-TGN), have been used for the
long-term and maintenance treatment of glucocorticoid-
dependent or glucocorticoid-refractory inﬂammatory bowel
disease (IBD) (Fig. 1). Recent publications, however, have chal-
lenged the place of AZA and 6-MP in the armamentarium for the
treatment of CD and UC1–3 (Table 1). In this article, a panel of
experts review the data and facts concerning AZA/6-MP to
answer the following questions: (1) what are AZA and 6-MP
and how do they work?, (2) which patient with IBD could beneﬁt
from AZA/6-MP?, (3) choice of monotherapy or combo therapy
with AZA/6-MP, (4) how to start, maintain, and when considering
to stop AZA/6-MP?, (5) AZA/6-MP adverse drug reactions:
patient information, prevention, and management, (6) special sit-
uations such as vaccination, surgery, pregnancy, and lactation
while on AZA/6-MP.
METHODS
A literature review on the use of AZA/6-MP was performed
focusing on the questions outlined above. The available literature
was assessed according to the GRADE approach (Grades of
Recommendation, Assessment, Development, and Evaluation).
The GRADE working group has developed a system for grading
the quality of evidence.4 The GRADE approach speciﬁes four
levels of quality (high, moderate, low, and very low). In a ﬁrst
step, the literature was ranked according to the evidence level, in
a second step factors were taken into account that can either
downgrade the evidence (such as risk of bias, inconsistency,
indirectness, imprecision, and publication bias), or upgrade the
evidence (such as a large consistent effect, dose response,
confounder only reducing the size of a particular effect). In a third
step, the ﬁnal grade (high, moderate, low, and very low) was
assigned. In a fourth step, factors were analyzed that can affect
a recommendation on the use of a particular measure (such as
balance of desirable and undesirable effects, cost-effectiveness,
and preference of patients). In the ﬁfth step, the recommendation
for the use of a particular measure was provided (strong for
using, weak for using, strong against using, and weak against
using). The grading of evidence and recommendation provided
here reﬂects the consensus of the panel, deﬁned as a $70%
majority vote.
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Question 1: What Are AZA/6-MP, How Do
They Work?
AZA/6-MP are purine analogs and act as immunosuppres-
sive/immunomodulating drugs. AZA/6-MP are metabolized
through a complex metabolic pathway to 6-TGN antimetabolites
that are incorporated into nucleic acid, thereby inhibiting DNA
replication and RNA, as well as protein synthesis.
AZA is a prodrug cleaved by glutathione-S-transferase to
6-MP, which is then metabolized to its active form through
a complex metabolic pathway. In a simpliﬁed manner, it involves
the following three main enzymes: thiopurine methyltransferase
(TPMT), xanthine oxidase, and hypoxanthine phosphoribosyl
transferase that convert 6-MP to 6-thiouric acid (inactive),
6-methylmercaptopurine (6-MMP), and precursors of the active
6-TGN. 6-TGN are antimetabolites, purine antagonists due to
their structural similarity that are incorporated into nucleic
acids and inhibit DNA replication. This ultimately prevents
T-lymphocyte proliferation leading to an immunosuppressive
activity. Other proposed mechanisms of action include inhibition
of several immune- and inﬂammation-related genes involved in
intestinal inﬂammation and trafﬁcking of leukocytes to the gut
such as tumor necrosis factor (TNF)–related apoptosis-inducing
ligand, TNF receptor superfamily member 7, and alpha-4-integrin
among activated but not resting T lymphocytes or through T-cell
apoptosis induction by blocking the CD28-dependent Rac1
protein activation.5–8
TPMT has several genetic variants that may result in
reduced or absent TPMT activity. Among whites, approximately
0.3% are homozygous for low enzyme activity (complete
deﬁciency), 11% are heterogeneous (partial deﬁciency), and
89% are homozygous for high enzyme activity (high activity).
An assay of TPMT activity in red blood cells (RBCs) or a TPMT
genetic test can identify patients with reduced TPMT activity,
allowing for the adjustment of AZA/6-MP dose (see below).5,9–17
Question 2: Which Patient with IBD Can
Beneﬁt from AZA/6-MP?
In CD, AZA/6-MP seem to offer no advantage over placebo
for the induction of remission or for clinical improvement but
permit the reduction of steroid consumption. However, AZA/
6-MP are less effective than anti–TNF-alpha drugs for the induc-
tion of steroid-free remission.
GRADE: high, recommendation: weak.
For induction of remission or clinical improvement in
active CD, AZA/6-MP offered no advantage over placebo in
a Cochrane review published in 2013, as 48% (107/225) of
patients achieved clinical improvement or remission with AZA/6-
MP compared with 36% (75/209) with placebo (8 studies, 434
FIGURE 1. Simpliﬁed metabolic pathway of thiopurines. 6-TU, 6-thiouric acid (inactive metabolite); GST, glutathione transferase (but nonenzymatic
process also active); HRPT, hypoxanthine phosphoribosyl transferase. Black blunt arrows indicate inhibitory pathway.
TABLE 1. Type, Frequency, Prevention and Management of AZA Adverse Reactions*
Name of Adverse Event Type Frequency and When Monitoring/Detection
Leukopenia Dose dependent 10%, anytime CBC, (6-TGN)
Agranulocytosis Dose dependent 0.3%, within 4–8 wk CBC, (TPMT activity)
Gastrointestinal intolerance +/2 Dose dependent 5%–20% within 6–8 wk None, (patient information)
Hepatitis Dose dependent 15%–28%, anytime but increases gradually overtime LFTs, (6-MMP)
Pancreatitis Dose independent 3%–15%, within 3 mo Lipase
Flu-like illness Dose independent 5%, within 2 wk (Patient information), body temperature
Rash Dose independent 4%, within 3 wk Patient information
*CBC, complete blood count; GM-CSF, granulocyte–monocyte colony-stimulating factor; LFT, liver function test.
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patients).18 However, a statistically signiﬁcant difference was
seen regarding steroid sparing (deﬁned as prednisone dose ,10
mg/d) between AZA versus placebo, as 64% (47/163) of AZA
patients were able to reduce their prednisone dose to ,10 mg/
d compared with 46% (32/70) of placebo patients (relative risk
[RR] 1.34, 95% CI: 1.02–1.77). Hazlewood came to the same
conclusion that AZA was not different from placebo for inducing
remission (odds ratio (OR) 1.2 95% credible interval of 0.76–2.1)
in his comparative effectiveness network meta-analysis.19 How-
ever, the technical review article by the American Gastroentero-
logical Association Institute comments that compared with
placebo, AZA/6-MP therapy showed a trend toward fewer failures
to achieve remission at 12 to 17 weeks (RR: 0.87; 95% CI:
0.71–1.06).20
The open-label RAPID treatment strategy trial by Cosnes
et al. compared the efﬁcacy of randomly assigned early treatment
(within 6 months after diagnosis) with AZA (2.5 mg$kg21$d21,
n ¼ 65) versus conventional management (AZA only in cases of
corticosteroid dependency, chronic active disease with frequent
ﬂares, poor response to corticosteroids, or development of severe
perianal disease, n ¼ 67).1 The study, conducted in 24 GETAID
French IBD centers, enrolled adults with a diagnosis of CD for less
than 6 months who were at risk of disabling disease (age ,40
years, active perianal lesions, and corticosteroid use within 3
months of diagnosis). Over an observation period of 3 years,
a median of 67% of trimesters were spent in steroid-free and
anti-TNF-alpha–free remission (interquartile range, 11%–85%) in
the AZA group, compared with 56% in the conventional man-
agement group (interquartile range, 29%–73%; P ¼ 0.69). There
was a statistically not signiﬁcant trend for a decreased proportion of
trimesters with any corticosteroid use. The median duration of
a signiﬁcant (i.e., .10 mg/d prednisone or .3 mg/d budesonide)
corticosteroid dose exposure per trimester was 9 days5,9,10,21–32 in
patients in the early AZA group, and 11 days10,11,18,24–34 in patients
in the conventional management group (P ¼ 0.052). Regarding the
secondary endpoints, there were no differences between the 2
groups in the proportions of trimesters with disease ﬂare, hospi-
talization, intestinal surgery, or the use of TNF antagonists. How-
ever, a higher cumulative proportion of patients in the AZA group
were free of perianal surgery than in the conventional management
group (96% 6 3% and 82% 6 6% at month 36, respectively; P ¼
0.036). The authors concluded that early AZA was not more
effective than conventional management in adult patients with
newly diagnosed CD in terms of lengthening the period on clinical
remission over 3 years after diagnosis.
In the double-blind, placebo-controlled AZathioprine for
Treatment of Early Crohn’s disease (AZTEC) trial (n ¼ 131),
AZA 2.5 mg/kg started within the ﬁrst 8 weeks after diagnosis
of CD was not associated with an increased rate of sustained
corticosteroid-free remission at week 76 compared with placebo
(44% versus 36%, P ¼ 0.48).2 The rates of relapse (deﬁned as
CDAI .175) and corticosteroid requirements were also similar
between the 2 groups. However, a post hoc analysis of relapse,
deﬁned as a Crohn’s Disease Activity Index (CDAI) score .220,
showed lower relapse rates in the AZA group than in the placebo
group (8/68 ¼ 12% versus 19/63 ¼ 30%; P ¼ 0.01). Panés et al.
concluded that early AZA was not more effective than placebo in
adult patients with newly diagnosed CD for achieving sustained
steroid-free remission over 76 weeks.
The fact that only 81 (60%) of the 136 randomized patients
in RAPID and 69 (53%) of the 131 in AZTEC trial completed the
studies and the relatively small sample sizes of the two studies
raise some concerns about the authors’ conclusions. In his com-
ment, Lakatos emphasizes that the interpretation should rather be
that patients with CD with a mild phenotype at diagnosis do not
necessarily beneﬁt from systematic early introduction of AZA
therapy.35 Nevertheless, inﬂiximab monotherapy outperformed
AZA monotherapy at week 26 for corticosteroid-free clinical
remission (44.4% versus. 30.0%; NNT 7) in the 2010 Study Of
biologic and immunomodulator Naive patients In Crohn’s disease
(SONIC) trial that randomized 508 treatment-naive, moderate-to-
severe, diagnosed (median disease duration of 2.3 years) patients
with CD to AZA, inﬂiximab, or a combination of both.19,36,37 A
post hoc analysis of the SONIC trial (n ¼ 188)38 evaluated dif-
ferent composite remission measures at week 26 in a subgroup of
patients with CD with CDAI scores, C reactive protein (CRP),
and endoscopic data available at baseline and week 26 (n ¼ 188).
Assessed composite remission measures were: clinical remission
(CDAI , 150) and mucosal healing (MH, absence of any muco-
sal ulcerations), also called as “deep remission,” and alternative
composite endpoints: clinical remission + normalized CRP (CRP
, 0.8 mg/dL); normalized CRP + MH; and clinical remission +
normalized CRP + MH. Seventy-two percent of the patients
achieved clinical remission, 48% achieved MH at week 26. All
composite outcomes were signiﬁcantly greater (Bonferroni signif-
icance level, P # 0.016) with combination therapy (i.e., inﬂixi-
mab and AZA; 52%–64%) versus AZA monotherapy (13%–29%;
P # 0.005 for all comparisons). Composite remission rates
including MH were signiﬁcantly greater with combination therapy
(52%–57%) versus inﬂiximab (26%–32%; P# 0.015 for all com-
parisons except normalized CRP + MH, P ¼ 0.017) and versus
AZA monotherapy (13%–20%; P # 0.002 for all comparisons).
In the SONIC trial, patients in the AZA group had only AZA to
induce remission, which may explain the lack of efﬁcacy (steroid-
free remission at week 26). This was in contrast with the Com-
bination Of Maintenance Methotrexate-Inﬂiximab Trial study
where patients received conventional steroids and in addition also
inﬂiximab and methotrexate or placebo.39
In CD, AZA (2–2.5 mg$kg21$d21) or 6-MP (1–1.5
mg$kg21$d21) are effective as maintenance therapy for patients:
1. Whose disease is chronically active or ﬂares frequently
2. Who are dependent on steroids, have experienced steroid-
related side effects, or for whom steroids no longer work, as
it reduces the need for steroid treatment.
GRADE: high, recommendation: strong.
In CD and in UC, corticosteroid-induced remission is
a common clinical scenario, and the discontinuation of
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corticosteroids is associated with high relapse rates.40,41 In addi-
tion, many patients whose disease is steroid dependent or refrac-
tory experience serious steroid-related side effects. Steroid-sparing
strategies are thus needed for a large proportion of patients exposed
to this class of medication.
In a Cochrane review by Prefontaine, AZA/6-MP have
been shown to have a positive effect on maintaining remission in
CD.42 Indeed, the OR for maintenance of remission with AZA
was 2.32 (95% CI: 1.55–3.49) with a NNT of 6, whereaas the one
with 6-MP was 3.32 (95% CI: 1.40–7.87, NNT of 4). Further-
more, a steroid-sparing effect was noted with AZA (OR of 5.22,
95% CI: 1.06–25.68, NNT of 3). When these maintenance therapy
data were analyzed for the effect of the AZA dose (range 1.0–2.5
mg$kg21$d21), the OR for response increased from 1.20 (95%
CI: 0.60–2.41) at 1.0 mg$kg21$d21 to 3.01 (95% CI: 1.66–5.45)
at 2.0 mg$kg21$d21 and to 4.13 (95% CI: 1.59–10.71) at 2.5
mg$kg21$d21. Furthermore, more patients seemed to respond to
AZA (71% maintained remission in pooled analysis) than to
6-MP (51% maintained remission). However, 1 study by Hanauer
et al,43 published in 2004, used a low dose of 6-MP (50 mg/d),
which may account for this difference.
In the setting of steroid resistant CD, however, the use of an
anti–TNF-alpha drug might be more appropriate than AZA/6-MP,
although no other trial than SONIC (follow-up until week 50)
directly compared the two drug classes. At week 50, the
corticosteroid-free clinical remission rate in SONIC was 24.1%
for AZA alone (n ¼ 170), 34.9% for inﬂiximab alone (n ¼ 169)
(P ¼ 0.03), and 46.2% for the combo therapy (n ¼ 169), P value
for combo therapy versus inﬂiximab alone ¼ 0.04 and P value for
combo therapy versus AZA alone ,0.001.36
In perianal ﬁstulizing, CD AZA/6-MP have limited impact,
thus anti-TNF treatment should be favored.
GRADE: moderate, recommendation: weak for using AZA/
6-MP.
No controlled clinical study evaluated AZA/6-MP as therapy
for CD with ﬁstula closure as a primary endpoint. A meta-analysis44
of 5 randomized placebo-controlled clinical trials in which ﬁstula
closure was a secondary endpoint showed beneﬁcial effects of
AZA/6-MP in 54% of cases, whereas only 21% responded to pla-
cebo (OR 4.4, 95% CI: 1.5–13.2).45 A limitation of this analysis was
that 66% of the pooled patients came from a single study. In another
meta-analysis, an odds ratio of 4.44 (95% CI: 1.5–13.2) favoring
healing or decreased discharge with antimetabolites was reported.44
In a third meta-analysis, looking at response rates to placebo in
patients with ﬁstulizing CD, Ford et al46 found a pooled rate of
15.6% (95% CI: 10.9%–20.9%) among all RCTs, for complete ﬁs-
tula closure. AZA/6-MP might therefore be used in ﬁstulizing CD
but would rarely be sufﬁcient alone. The panel thus recommends that
anti-TNF treatment with inﬂiximab, adalimumab, or certolizumab
pegol47,48 should be used as an integral part of the combined medical
and surgical therapeutic approach to ﬁstulizing CD, in line with the
ECCO recommendations.49
In CD, AZA/6-MP seem to be effective for maintenance of
surgically induced remission, although efﬁcacy outcomes
between AZA/6-MP and 5-aminosalicylic acid (5-ASA) agents
are uncertain.
AZA/6-MP prescription postoperatively is recommended in
the presence of:
1. Intolerance to 5-ASA
2. Poor prognostic factors (high relapse rate, penetrating dis-
ease, repeat surgery, multiple admissions for ﬂares,
involvement of the upper gastrointestinal tract, early age
at diagnosis, smoking, and extensive ulceration of the
mucosa)
3. Ulcerations at the endoscopic control 6 months postsurgery
(Rutgeerts’ score $i2).
GRADE: moderate, recommendation: weak.
The panel recommends furthermore to step up to an anti-
TNF agent in case of Rutgeerts’ score $i2 at the endoscopic
control in patients already under AZA/6-MP.
Based on 2 small studies, AZA/6-MP (n ¼ 168) are supe-
rior to placebo for maintenance of surgically induced remission in
patients with CD. In the AZA/6-MP group, 48% of patients expe-
rienced a clinical relapse compared with 63% of placebo patients
(RR 0.74, 95% CI: 0.58–0.94).43,50 A pooled analysis of ﬁve
studies (n ¼ 425 patients) showed no difference in clinical relapse
rates at 1 or 2 years between AZA/6-MP and 5-ASA agents. In the
AZA/6-MP group, 66% of patients had a clinical relapse com-
pared with 54% of 5-ASA patients (RR 1.15, 95% CI:
0.99–1.34).18
In a Cochrane systematic review, one small study, which
used intravenous or oral methotrexate (25 mg/wk), showed no
statistically signiﬁcant difference between methotrexate and AZA;
44% of patients under methotrexate (12/27) failed to enter
remission, compared with 37% of patients under AZA (RR
1.20, 95% CI: 0.63–2.29).41
De Cruz (n ¼ 174) conducted a strategy comparison trial
aimed at the identiﬁcation of the optimal strategy to prevent post-
operative disease recurrence—The Post-Operative Crohn’s Endo-
scopic Recurrence (POCER) treat-to-target study.51 The authors
compared standard treatment comprising 3 months of metronida-
zole tailored to clinical risk stratiﬁcation of recurrence (low risk:
no treatment, high risk (smoker, perforating disease, $second
operation): thiopurine, high risk and thiopurine intolerant: adali-
mumab) to colonoscopy at 6 months with treatment step-up in
case of recurrence (i.e., Rutgeerts’ score $i2) (thiopurine, fort-
nightly adalimumab with thiopurines, or weekly adalimumab).
The second strategy was the best therapeutic strategy for preven-
tion of postoperative CD recurrence. At 18 months, endoscopic
recurrence occurred indeed in 60 (49%) patients in the active care
group (colonoscopy at 6 months) compared with 35 (67%)
patients in the standard care group (no colonoscopy), P ¼ 0.03.
Complete mucosal normality was maintained in 27 (22%) of 122
patients in the active care group versus 4 (8%) in the standard care
group (P ¼ 0.03), with no differences in incidence and type of
adverse and severe adverse events. Furthermore, Savarino showed
in a randomized trial (n ¼ 51) that the rate of endoscopic
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recurrence at 2 years after ileocolonic resection was signiﬁcantly
lower on adalimumab (6.3%) compared with AZA (64.7%) or
mesalamine (83.3%).52 Clinical recurrence (12.5%) was also
signiﬁcantly lower and quality of life signiﬁcantly higher IBD
Questionnaire score (IBDQ ¼ 220) in the ADA group compared
with the AZA 2 mg$kg21$d21 (64.7%, IBDQ ¼ 90) and mesal-
amine groups 3 g/d (50%; IBDQ ¼ 98).
In UC, AZA/6-MP is recommended for patients who:
1. Have failed or cannot tolerate mesalamine or sulfasalazine
2. Require repeated courses of steroids.
GRADE: moderate, recommendation: strong.
Like in CD, therapeutic strategies in UC aim to treat ﬂares
and prevent recurrence of the disease. For a mild to moderate
disease, 5-ASA is the treatment of choice for ﬂares and the
maintenance of remission. In case of severe ﬂares or 5-ASA
inefﬁciency/intolerance, corticosteroids remain the ﬁrst choice to
induce remission, but their tapering/discontinuation is associated
with high rates of relapse. In addition, many patients whose
disease is steroid dependent or refractory experience steroid-
related side effects. Steroid-sparing strategies are thus needed for
a large proportion of patients exposed to this class of medica-
tion.40,53,54 Furthermore, the recently approved introduction of
MMX-budesonide for the treatment of UC is likely to renew the
problem of steroid dependence.54
In a prospective single-center study in the UK where the
use of biological therapies for chronic relapsing and remitting UC
is not routinely allowed in accordance with National Institute for
Health and Care Excellence guidance, all patients with UC treated
with AZA were identiﬁed from an electronic database. There were
164 (64.3%) of 255 patients who were still receiving AZA at the
last follow-up, of whom 154 (60.4%) were considered to have
achieved sustained clinical beneﬁt.55
Fraser reviewed the charts of patients attending the
Oxford IBD clinic from 1968 to 1999. The overall remission
rate under AZA—remission was deﬁned as no need for oral
steroids for at least 3 months and relapse as active disease
requiring steroids—was 58% (n ¼ 346). For patients in receipt
of more than 6 months of treatment, remission rates were 87%.
Interestingly, there was no difference in relapse rates between
CD and UC.56
A Cochrane review pooled six studies (n ¼ 286) of mostly
poor quality, comparing AZA, 6-MP, placebo, mesalamine, or
sulfasalazine for a duration of at least 12 months. AZA was better
than placebo for maintenance treatment, as 56% of patients treated
with AZA were disease free after 1 year of treatment compared
with 35% of patients who received placebo. Therefore, given the
established effectiveness and safety of aminosalicylates (i.e., me-
salamine or sulfasalazine) for remission maintenance in UC,
AZA/6-MP cannot be recommended as ﬁrst-line treatment in this
setting. However, AZA/6-MP may be an effective maintenance
treatment of patients who have failed or cannot tolerate mesal-
amine or sulfasalazine and for patients who require repeated
courses of steroids.57
The randomized double-blind UC-SUCCESS trial evalu-
ated the efﬁcacy and safety of 16 weeks of treatment with
inﬂiximab monotherapy, AZA monotherapy, or the combo
therapy of both in anti–TNF-naive moderate-to-severe UC. Pa-
tients treated with the combo therapy were statistically signiﬁ-
cantly more likely to achieve corticosteroid-free remission at
week 16 than those receiving inﬂiximab alone (40% [31 of 78]
versus 22% [17 of 77; P ¼ 0.017]) or AZA alone, 24% (18 of 76;
P ¼ 0.032). Furthermore, the combination therapy led to signif-
icantly better MH than AZA monotherapy.58
Armuzzi et al investigated the long-term outcome of
consecutive patients with steroid-dependent UC treated with
inﬂiximab. At the median duration of follow-up of 41.5 months
(interquartile range 26–45), 64% (46/96) of patients showed a sus-
tained clinical response, and colectomy-free survival was 77%.
Combo therapy was an independent predictor of sustained clinical
response (P , 0.0001). AZA/6-MP–naive status was protective
from colectomy (P ¼ 0.025). In this study, Mayo endoscopic
subscore of 3 at baseline (P ¼ 0.04) and high CRP after induction
(P ¼ 0.001) were independent predictors of colectomy.25
In view of efﬁcacy, cost, safety, and tolerability issues, the
panel recommends thiopurine maintenance therapy for patients
with a low risk of disease progression (i.e., moderate activity, and
not deﬁned as at high risk of disease progression, see below) who
responded to corticosteroids. For corticosteroid-dependent pa-
tients or patients at high risk of disease progression (extensive
severe colitis, ﬂares requiring hospitalization, high erythrocyte
sedimentation rate, or high concentration of C-reactive protein),
the panel recommends an anti-TNF agent, either as monotherapy
or preferably in combination with a thiopurine, in accordance with
the Toronto consensus,30 it should indeed be noted that, in the
UC-SUCCESS trial, compared with the combo therapy, those
receiving inﬂiximab alone performed slightly worse (22%
[17 of 77; P ¼ 0.017]) than patients receiving AZA alone,
(24% [18 of 76; P ¼ 0.032]), or vedolizumab (with the exception
of fulminant colitis due to lack of data).
AZA/6-MP can induce MH in CD and in UC.
GRADE: moderate.
MH has emerged as an important treatment goal for patients
with IBD as it is associated with sustained clinical remission, as
well as reduced rates of hospitalization and surgical resection. In
UC, MH may represent the ultimate therapeutic goal because
inﬂammation is limited to the mucosa. In CD, which is a trans-
mural disease, MH can be considered as an initial event in the
suppression of inﬂammation of deeper layers of the bowel wall
rather than as a sign of complete healing of gut inﬂammation; for
that reason, it is viewed by some as a minimum therapeutic
goal.59,60 Few original data have been published on that topic but
the data indicate that AZA is able to induce and maintain MH.
D’Haens61 showed in 2 studies that AZA can lead to MH.
In severe recurrent Crohn’s ileitis after ileocecal resection, 15 of
19 patients treated with AZA have been reevaluated by endoscopy
or radiology. AZA therapy resulted in induction and maintenance
of clinical remission in all 15 patients for at least 6 months after
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complete weaning off corticosteroids. Complete macroscopic
healing of the neoterminal ileum was observed in 6 of 15 patients,
near-complete healing with only superﬁcial erosions remaining in
5 of 15 patients, partial healing in 3 of 15 patients, and unchanged
inﬂammatory lesions in 1 patient. D’Haens62 also studied MH in
20 patients with CD on AZA with long standing steroid-free
remission i.e., taking AZA for at least 9 months (mean duration
24.4 6 13.7 months) and no corticosteroids for at least 3 months.
He showed that full MH could be achieved in 54% (7/13) of
patients with ileitis, and 70% (14/20) with colitis with most of
the remaining patients having at least partial healing, and only
a small minority experienced no healing at all (1/20 for colitis and
1/13 for ileitis). Mantzaris et al63 also showed the healing poten-
tial of AZA in a controlled study. This study showed the superi-
ority of AZA (n ¼ 38) over budesonide (n ¼ 39) in patients with
steroid-dependent Crohn’s ileocolitis or proximal colitis who had
achieved clinical remission on conventional steroids, as complete
or near-complete healing was achieved in 83% of AZA-treated
patients compared with only 24% of budesonide-treated patients
(P , 0.0001). In the SONIC trial, MH occurred in 16% of pa-
tients receiving AZA monotherapy, 30% of patients receiving
inﬂiximab monotherapy, and 44% of patients receiving combo
therapy at week 26.36 In the above-mentioned post hoc analysis
of the SONIC trial, 48% of patients with CD achieved MH at
week 26, and combination therapy (i.e., inﬂiximab and AZA) was
signiﬁcantly more effective than AZA or inﬂiximab monother-
apy.38 A 2014 Effective Health Care Program comparative effec-
tiveness review found moderate strength of evidence for the
beneﬁt of inﬂiximab over AZA for MH, as well as the beneﬁt
of combo therapy over AZA for disease activity and MH. How-
ever, the data used for analysis were almost entirely drawn from
the SONIC trial.22,36
Limited data are available to assess thiopurines-mediated
MH in UC. An open-label study with AZA64 showed MH in 22/
32 (69%) patients after at least 6 months therapy, indicating that
MH may be maintained with AZA. Another study found that
AZA therapy for 6 months resulted in MH and complete remis-
sion in 19/36 (53%) patients with UC compared with 7/36 (19%)
patients on 5-ASA.24 As already mentioned above, MH at week
16 in the UC-SUCCESS trial was achieved in 63% (49 of 78) of
the combo therapy (inﬂiximab and AZA) group versus 55% (42 of
77, P ¼ 0.295) of the inﬂiximab alone group and 37% (28 of 76,
P ¼ 0.001) of the AZA alone group.58
Question 3: Choice of Monotherapy or
Combo Therapy?
In CD, the combination of AZA/6-MP and inﬂiximab
(combo therapy) is superior to inﬂiximab alone for the induction
of steroid-free remission.
1. Severe CD, characterized by early disease onset, extensive,
and deep intestinal ulcerations or complex ﬁstulizing peria-
nal disease, may beneﬁt from combo therapy with AZA/
6-MP and an anti–TNF-alpha drug (especially inﬂiximab,
as the value of combo therapy in adalimumab or certolizu-
mab studies has not been shown convincingly) to maximize
rapid control
2. Six months to 1 year of combination therapy is recommen-
ded, with no data available for longer duration.
GRADE: high, recommendation: strong.
In UC, combo therapy for 16 weeks with AZA/6-MP and
inﬂiximab seems to be the best option for moderate to severe UC
in anti-TNF-alpha-naive patients. There are, however, no data for
longer treatment durations.
GRADE: high, recommendation: strong.
In the Cochrane review published in 2013, the combination
of AZA and inﬂiximab was signiﬁcantly superior to inﬂiximab
alone for the induction of steroid-free clinical remission in CD, as
66% (116/194) of patients under combo therapy achieved steroid-
free remission compared with 48% (91/189) of patients on
inﬂiximab alone (2 studies, 383 patients; RR 1.23, 95% CI
1.02–1.47).18 In a technical review by the American Gastroenter-
ological Association Institute, the authors performed an analysis,
combining data from the SONIC study and a study by Lemann
that compared therapy with inﬂiximab (3 doses) plus AZA (n ¼
58) with AZA/6-MP therapy alone (n ¼ 57). Fewer patients failed
to achieve remission in the combo group than in the AZA group
(RR, 0.61; 95% CI: 0.52–0.73). The use of combo therapy
reduced the number of remission failures as compared with
AZA therapy alone by 274 per 1000 patients, without signiﬁcant
difference in the rates of serious infections.20,65
Based on a network meta-analysis, inﬂiximab plus AZA or
adalimumab seem to be the most effective therapies for the
induction and maintenance of remission in CD.19 In the SONIC
trial that included only patients naive to immunomodulators,
combo therapy at week 26 was associated with higher rate of
corticosteroid-free clinical remission than inﬂiximab monotherapy
(56.8% versus 44.4%; NNT 8) and AZA monotherapy (56.8%
versus 30.0%; NNT 4). At week 50, 24% of patients on AZA
monotherapy achieved steroid-free remission compared with 35%
of patients receiving inﬂiximab monotherapy and 46% of patients
receiving combo therapy.36 Combo therapy was better than mono-
therapy in terms of MH rates, clinical remission, disease severity
rating, and quality of life rating.22,36
In the SONIC trial, patients in the AZA group had only
AZA to induce remission which may explain the lack of efﬁcacy
(steroid-free remission at week 26). This was in contrast with the
Combination Of Maintenance Methotrexate-Inﬂiximab Trial in
which patients received conventional steroids and additionally
inﬂiximab and methotrexate or placebo (Feagan BG Gastroenter-
ology. 2014;146:681–688). In Combination Of Maintenance
Methotrexate-Inﬂiximab Trial, a 50 weeks double-blind
placebo-controlled trial with 126 patients, the combination of
inﬂiximab and methotrexate, although safe, was actually no more
effective than inﬂiximab alone (30.6 versus 29.8% of actuarial
rate of treatment failure, respectively) in patients with CD
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receiving treatment with prednisone as induction therapy within
the preceding 6 weeks.39
A meta-analysis by Jones66 questioned whether patients
with CD who start anti-TNF therapy after failed immunomodula-
tor therapy (subgroup of patients from 11 randomized controlled
trials) should continue to receive concomitant immunomodula-
tors. Overall, combination therapy was no more effective than
monotherapy in inducing 6 months remission, inducing
a response, maintaining a response, or inducing partial or com-
plete ﬁstula closure. Similarly, in subgroup analyses of individual
anti–TNF-alpha agents, combination therapy was not more effec-
tive than anti-TNF monotherapy in inducing 6 months remission.
Combination therapy was not associated with an increase in
adverse events, in contrast to other published data.38 However,
the beneﬁt of combo therapy may extend to preventing the long-
term loss of response to inﬂiximab as it is associated with lower
CRP levels67 and fewer trimesters with CD ﬂares.68
In the UC SUCCESS,58 which included only anti–TNF-
naive adults, 10% of whom had previous AZA or ciclosporine,
combo therapy was shown to be the best option for moderate to
severe UC to achieve steroid-free remission at week 16. However,
there are no data for longer durations, and thus the therapeutic
strategy beyond 16 weeks remains unclear. The combo therapy
group also had the best percentage of MH at week 16 with 63%
(49 of 78) versus 55% (42 of 77; P ¼ 0.295) for the inﬂiximab
alone group and 37% (28 of 76; P ¼ 0.001) for the AZA alone
group.
The combination of methotrexate and inﬂiximab does not
seem to provide any additional beneﬁt over inﬂiximab mono-
therapy. However, the available studies were, comparatively,
small; further research is thus needed to determine the role of
methotrexate when used in conjunction with inﬂiximab or other
biological therapies.41
In a retrospective study by Ben-Horin, addition of AZA/6-
MP (n ¼ 3) or methotrexate (n ¼ 2) to inﬂiximab was shown28 to
gradually decrease levels of antibodies to inﬂiximab, whereas
trough levels of inﬂiximab increased and clinical response was
restored.
There are several hypotheses why combo therapy may lead
to greater efﬁcacy. One reason may be the additive immunosup-
pressive effect, for example through a synergistic effect on
apoptosis induction.69 Another relevant mechanism might be the
prevention of immunogenicity. Indeed, combo therapy has been
shown to be associated with higher inﬂiximab trough levels36 and
to reduce inﬂiximab clearance, as well as the formation of anti-
bodies to inﬂiximab (ATI). ATI can cause infusion reactions and
loss of response.26,70 Combo therapy lowers the incidence of
antidrug–antibodies for all anti–TNF-alpha agents, regardless of
the origin of the protein sequence (chimeric, humanized, and
human) and the disease population (rheumatoid arthritis and
IBD), as they can block the expansion of activated immune cells.
This pharmacological effect of AZA and 6-MP is considered the
underlying mechanism to explain the inhibition of the anti–TNF-
alpha drugs immunogenicity.36,71–74
Question 4: How to Start, Maintain, Monitor,
and Stop AZA Treatment?
There are 2 dosing strategies for AZA and 6-MP: the ﬁrst
one is empiric weight-based dosing, the second one is based on
TPMT phenotyping (activity measurement).
1. There is a lack of studies evaluating how quickly the AZA
dose can be increased. Some clinicians start directly with
the target dose of 2.0 to 2.5 mg$kg21$d21 for AZA and 1.0
to 1.5 mg$kg21$d21 for 6-MP. Others start at low dose
(50 mg or 1 mg$kg21$d21 for AZA and 25 mg or
0.5 mg$kg21$d21 for 6-MP) and then increase to the full
dose or increase the dose every second week to reach
the target dose
2. Determining TPMT activity may reduce the time to thera-
peutic drug levels and reduce side effects.
Complete blood counts and liver tests should be performed
every week during the ﬁrst month, then every second week for the
next 2 months (the European Summary of Product Characteristics
recommends a weekly blood count during the 8 ﬁrst weeks of
treatment), and then every 3 to 4 months as myelotoxicity and
hepatotoxicity may also develop as late complications.
Measuring 6-TGN and 6-MMP metabolites in erythrocytes
may be used to monitor therapeutic drug levels and patient’s
compliance and to lower the risk of toxicity.
GRADE: low, recommendation: weak.
AZA absorption in healthy subjects ranges between 16%
and 50%. The molecular weight of 6-MP is 55% of AZA’s, and
88% of AZA is converted to 6-MP. A conversion factor of 0.5 is
therefore used to convert AZA dosing into 6-MP dose.75
It is a question whether to start with AZA or with 6-MP. A
Cochrane review concluded that AZA and 6-MP are both more
effective than placebo for maintenance of remission in CD.
However, higher response rates were obtained with AZA than
6-MP. However, the one study evaluating 6-MP used a relatively
low dose of the drug.76
There are 2 dosing strategies for AZA and 6-MP. The ﬁrst
one is empiric weight-based dosing and the second one is based
on TPMT phenotype testing (enzyme activity measurement; this
should not be measured in patients who have received recent
blood transfusions). TPMT genotyping (usually performed by
single-nucleotide polymorphism analysis and mutation detection)
has indeed less sensitivity and is less cost-effective than
phenotyping in predicting the risk of leukopenia.77 However, out-
side of the USA, TPMT enzyme activity measurement is not
universally and readily available, and not universally covered
by health insurances.
Some clinicians start immediately with the target dose of
2.0 to 2.5 mg$kg21$d21 for AZA and 1.0 to 1.5 mg$kg21$d21 for
6-MP, whereas others start at low dose (50 mg or 1 mg$kg21$d21
for AZA vs. 25 mg or 0.5 mg$kg21$d21 for 6-MP) and then
increase to the full dose or increase the dose by 50 mg every 2
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or 4 weeks to reach the target dose. Some advocate measurement
of TPMT activity5,18 to start directly with the full dose or to
increase the dose toward the target dose more rapidly, and to
reduce potential adverse reactions. TPMT activity measurement
may indeed reduce time to therapeutic response and minimize
toxicity, in particular leukopenic events.78 High TPMT activity
is associated with lower 6-TGN and higher 6-MMP levels, poten-
tially explaining reduced response rates and increased hepatotox-
icity.16 In case of intermediate to high TPMT activity, the AZA/
6-MP dose might be rapidly escalated toward therapeutic drug
levels. By contrast, low TPMT activity requires initial dose reduc-
tion and slower dose escalation to avoid toxicity.79
Measuring 6-TGN and 6-MMP metabolites in erythrocytes
can be used to monitor therapeutic drug levels, patient compli-
ance, and risk of toxicity (Table 3). AZA/6-MP therapeutic efﬁ-
cacy has been associated with 6-TGN levels.235 pmol/8 · 10E8
erythrocytes, whereas risk of leukopenia correlates with 6-TGN
level .450 pmol/8 · 10E8 erythrocytes, and risk of hepatotoxic-
ity with 6-MMP level .5700 pmol/8 · 10E8 erythrocytes.13
Osterman et al80 pooled the available data of previous studies
(they identiﬁed 55 articles, 12 of which contained data suitable for
inclusion) to provide a more precise estimate of the association
between 6-TGN levels and IBD activity. The mean/median
6-TGN levels were higher among patients in remission than in
those with active IBD (pooled difference, 66 pmol/8 · 108 RBCs;
95% CI, 18–113; P ¼ 0.006), but with signiﬁcant heterogeneity.
Excluding the 1 outlier study eliminated this heterogeneity. Patients
with 6-TGN levels above the threshold value of 230 to 260 pmol/8
· 108 RBCs were more likely to be in remission (62%) than those
below the threshold value (36%) (pooled odds ratio, 3.3; 95% CI:
1.7–6.3; P , 0.001), but with signiﬁcant heterogeneity. Again,
excluding the 1 outlier study eliminated this heterogeneity.
Recently, Moreau81 performed a meta-analysis on 17 stud-
ies enrolling 2049 patients with IBD and clearly established an
association between 6-TGN levels and clinical remission rates in
patients with IBD and explained the heterogeneity of results
among selected studies by the lack of standardization in 6-TGN
assays. Including only studies using the reference method by
Lennard et al (n ¼ 10), the pooled odds ratio for clinical remission
among patients with 6-TGN levels over a cutoff value between
230 and 260 pmol/8 · 108 RBC was 3.15 (95% CI: 2.41–4.11).
In the absence of studies evaluating how quickly an AZA/
6-MP dose can be increased, we recommend a dose increase every
second week, provided the medication is well tolerated and in the
absence of hematologic toxicity (in particular white blood cell
count .4 · 10E3/L). Complete blood counts and liver function
tests should be regularly monitored, irrespective of the chose initial
dose. TPMT genotyping or phenotyping cannot be a substitute, but
could help choosing the appropriate dose,82 We propose monitoring
complete blood counts and liver function tests every week for the
ﬁrst month, then every second week for the 2 following months,
and then every 3 months,5 as leukopenia and hepatotoxicity can
also occur as a late adverse drug reaction (Fig. 2).
TABLE 3. Interpretation and Required Intervention
According to Thiopurines Metabolite (6-TGN/6-MMP)
Results
Overdose/ reduce the dose with
active disease—refractoriness
to thiopurines/ add or switch
to an induction drug (e.g.,
steroids or anti-TNF agents)
High TPMT activity (“shunt” of
the metabolism/ leads to
inefﬁcacy of treatment)
Low or deﬁcient TPMT activity
/ reduce the dose (to
30%–50%) or stop (depending
of the myelotoxicity) and
consider measuring TPMT
activity (for assessment of risk)
poor patient compliance/
patient education or underdosed
/ increase the dose
Tested in the framework of a stable dose (at least 2–3 weeks).
FIGURE 2. AZA therapy introduction and monitoring scheme. Proposed screening, dosing, and surveillance scheme for the introduction of AZA/6-
MP introduction. CBC, complete blood counts; EBV, Epstein–Barr virus; HBV, Hepatitis B virus serology; LFTs, liver function tests; Mo, months; TB,
tuberculosis screening; W, week.
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Mesalamine and sulfasalazine have been shown in some
studies to increase 6-TGN levels in 82% of study patients in 1
study and 100% in another study, possibly as the consequence of
TPMT inhibition. This effect should therefore increase therapeutic
efﬁcacy and decrease side effects such as hepatotoxicity. How-
ever, this combination therapy has been associated with increased
rates of myelotoxicity, although the available data are to some
extent contradictory.83
For that reason, in accordance with Amin et al, we propose
to consider the preventive reduction of the AZA/6-MP dose by
25% combined with continuous laboratory monitoring.5,84,85
In patients with CD and UC with long-term clinical and
endoscopic remission, an interruption of AZA/6-MP may be
considered after 4 years of therapy.
GRADE: moderate, recommendation: weak.
When patients with CD achieve sustained steroid-free
remission under AZA, it is usually stable and long standing. A
controlled withdrawal study from the GETAID indicated sus-
tained remission over more than 5 years in 80% of patients when
treatment was continued, compared with 40% of patients when it
was stopped.86 In another study on patients with CD in remission
for .3.5 years under AZA, the remission rate was higher after 18
months if AZA therapy was not interrupted, as 3 patients suffered
a relapse in the AZA group (n ¼ 40) and 9 in the placebo group
(n ¼ 43). Kaplan–Meier estimates of the relapse rate at 18 months
were 8% 6 4% and 21% 6 6%, respectively.87 In a single-center
retrospective study, Oussalah et al. assessed the cumulative
probability of inﬂiximab failure in patients with CD in remission
who stopped AZA after receiving inﬂiximab in combination with
AZA for at least 6 months. Survival without inﬂiximab failure
was 85% (65%) at 12 months, and 41% (618%) at both 24 and
32 months in 48 patients with CD.88
Patients with UC who discontinue AZA or 6-MP treatment
have a high relapse rate, as 87% of complete responders who
discontinued 6-MP subsequently relapsed89; after AZA with-
drawal, a third of the patients relapsed within 12 months, half
within 2 years, particularly in case of history of extensive colitis,
lack of sustained remission during AZA maintenance or in case of
short treatments (3–6 months).33 Few data help us to decide when
considering a discontinuation of AZA/6-MP. In his retrospective
Oxford IBD clinics study, Fraser showed that after discontinuing
AZA while still in remission, the percentage of patients with UC
and patients with CD (n ¼ 222) remaining in remission at 1, 3,
and 5 years was 63%, 44%, and 35%, respectively; it is interesting
to note that the duration of AZA treatment did not affect the
relapse rate after treatment discontinuation.56 In a multicenter ret-
rospective cohort study from 11 centers across the UK, Kennedy
et al investigated the success of planned thiopurines withdrawal
(with continuous thiopurines use $3 years) in 237 patients (129
CD, 108 UC) in sustained clinical remission. The median duration
of thiopurines use before withdrawal was 6.0 years (interquartile
range 4.4–8.4). At 1 year postwithdrawal, moderate/severe relap-
ses were observed in 23% patients with CD and 12% patients with
UC (P ¼ 0.035), and at 2 years in 39% patients with CD versus
26% patients with UC.17
In a review article on “Why, when and how to de-escalate
therapy in inﬂammatory bowel diseases,” Pariente and Laharie
calculated that in patients receiving AZA/6-MP alone, relapse rate
TABLE 2. Vaccine Characteristics and Use During Immunosuppressive Therapy with AZA/6-MP (Adapted from
Refs. 42,45,76)
Vaccine Type Vaccine Target Antigen Type Restriction of Use
Prevaccination
Washout Period
Postvaccination
Waiting Period efore
AZA Therapy
Inactivated
vaccines
Diphtheria, tetanus, pertussis,
poliomyelitis, Hepatitis A,
Hepatitis B, tick-borne
encephalitis
Proteins No restriction No wash out 1 mo
Haemophilus inﬂuenza type b,
Pneumococcus (PCV 13 and
PPSV 23), Meningococcus C,
Meningococcus ACW135Y,
typhoid (injectable)
Polysaccharides
(conjugated or not)
Human papilloma virus Virus-like particles
Live vaccines Measles-mumps-rubella, varicella,
zoster, yellow fever, typhoid 21a
(oral), rotavirus, tuberculosis
(BCG)
Living particles Contra-indicated .3 mo 1 mo
Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the original work
and from the owner of copyright in the translation or adaptation.
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at 12 months after AZA/6-MP cessation was around 20% in CD
and 30% in UC.90 A multidisciplinary European expert panel on
“When do we dare to stop biological or immuno-modulatory ther-
apy for CD” considered it appropriate to stop AZA/6-MP mono-
therapy after 4 years of clinical remission; for combo therapy,
anti–TNF-alpha withdrawal, while continuing the immunomodula-
tor, was considered appropriate after 2 years of clinical remission.91
We recommend performing thorough clinical and biolog-
ical monitoring before stopping AZA in UC and in CD—stool
calprotectin, CRP, WBC, colonoscopy, and imaging—and to con-
sider deescalation only in the presence of clinical and biological
remission, including MH. We propose to continue the regular
monitoring of stool calprotectin levels after drug withdrawal.
Question 5: AZA Adverse Drug Reactions,
Patient Information, Prevention,
and Management?
Around 15% to 20% of patients have to discontinue AZA
because of adverse drug reactions. Myelosuppression and hepa-
totoxicity are generally dose dependent and related to intracellular
concentration of active metabolites. Severe adverse drug reactions
are encountered only rarely if the dose does not exceed 2.5
mg$kg21$d21 (AZA) or 1.5 mg$kg21$d21 (6-MP).18 However,
the development of leukopenia, anemia, or pancytopenia, due to
the accumulation of the active 6-TGN metabolite, can be observed
months to years after the initiation of therapy.92 Hepatotoxicity
but also in some cases nausea, myalgia, and fatigue, seem to be
associated with the production of the methylated 6-MMP prod-
ucts. In 15% to 20% of patients (“hypermethylators”), this mech-
anism is exacerbated. A high TPMT activity (.14 U/mL RBC)
indeed results in more 6-MMP, which leads to increased hepato-
toxicity,5,16 whereas low TPMT activity is associated with high 6-
TGN levels and thus myelotoxicity.
Blocking xanthine oxidase with allopurinol and reducing
the AZA dose to only a quarter—as concomitant prescription of
allopurinol and AZA/6-MP can lead to severe myelotoxicity—can
solve this issue and optimizes the proportion of active metabo-
lites.93,94 Indeed, some pharmacodynamics studies have shown
that the combination therapy for allopurinol with low-dose 6-
MP or AZA (25%–33% of normal weight–based dose) resulted
in increased 6-TGN levels while decreasing 6-MMP, and thus
decreasing 6-MMP/6-TGN ratios, thereby reducing hepatotoxicity
and enhancing therapeutic efﬁcacy. This is due to the observations
that 6-MMP levels correlate with a risk of hepatotoxicity if levels
exceed 5700 pmol/8 · 108 RBCs. However, the exact mechanism
of action of allopurinol, a shunt of the metabolization toward the
favored 6-TGN, remains not clearly understood, as the inhibitory
effect of allopurinol includes xanthine oxidase and the TPMT.
This approach requires extremely careful monitoring and should
be restricted to experienced IBD centers.34,95
Adverse gastrointestinal events are frequent. In mild cases
of gastrointestinal intolerance, taking the medication before
sleeping or splitting the dose can help to control symptoms. For
more severe cases, a switch to 6-MP is a good option.
GRADE: low, recommendation: weak.
Adverse gastrointestinal events mostly encountered in daily
practice are nausea, vomiting, and/or abdominal pain. In case of
mild gastrointestinal intolerance, taking the medication before
sleeping or split-dose administration (2 or 3 times per day) can
help to control symptoms. Another option is to switch from AZA to
6-MP, as these symptoms seem to be linked to the imidazole
derivative.96 Shih et al. found that dividing the total daily thiopur-
ines dose (e.g., 75 mg twice a day instead of 150 mg once daily) led
to a reduction in 6-MMP levels (11,785 versus 5324; P ¼ 0.0001)
without reducing 6-TGN levels (239 versus 216, P ¼ NS) or the
clinical disease activity. Furthermore, elevated transaminases and
ﬂu-like symptoms resolved in 18 of 20 patients studied.97
Dose-independent adverse reactions, such as pancreatitis,
ﬂu-like syndrome, and rashes are reported less frequently. In case
of pancreatitis, further use of any kind of thiopurines is contra-
indicated as the mechanism is thought to be allergic or
idiosyncratic. Recently, Heap et al. performed a genome-wide
association study on 172 cases and 2035 controls with IBD, and
identiﬁed strong evidence of an association within the class II
HLA region. It seems that HLA-DQA1-HLA-DRB1 variants
confer susceptibility to pancreatitis induced by thiopurines
immunosuppressants.98 However, this view has been recently
challenged in a case report of 2 pediatric patients successfully
treated with 6-MP after AZA pancreatitis99 Owing to numerous
false-positive results, there should be no routine monitoring of
lipase levels, but of typical symptoms. When the drug is stopped,
lipase level usually returns to reference range within a few days.
Patients should be advised that the long-term use of AZA/6-MP
(mostly .2 years) alone or in combination with anti–TNF-alpha
agents has been associated with a slightly increased risk of lymphoma,
nonmelanoma skin cancer, and urinary tract cancer.
Skin follow-up by a dermatologist should be performed
once a year in white patients. Patients should avoid excessive sun
exposure and use a high-factor sun block.
The risk of cervix dysplasia and cancer is also increased
and requires annual check-ups.
GRADE: moderate, recommendation: strong for the above
surveillance strategy.
The long-term use of AZA/6-MP (mostly .2 years) as
monotherapy or combo therapy has been associated with the
development of lymphoproliferative disorders,27,100–104 urinary
tract cancer,105 and nonmelanoma skin cancers (basal cell carci-
noma and squamous cell carcinoma).106–108 For dark skin types
less vulnerable to skin cancer development induced by exposure
to ultraviolet radiation from the sun, check-ups every 2 to 3 years
are probably sufﬁcient (weak evidence).
Subgroups of patients at higher risks have been identiﬁed:
combo therapy in males ,30 years for hepatosplenic T-cell lym-
phoma,109 and mono-AZA therapy in patients .65 years for
lymphoproliferative disorders.27 Lymphoma risk is thus the major
limiting factor of the prolonged use of AZA/6-MP, but the abso-
lute cumulative risk of lymphoproliferative disorder remains
extremely low, ,1% after 10 years of exposure.27
Mottet et al Inﬂamm Bowel Dis  Volume 22, Number 11, November 2016
2742 | www.ibdjournal.org
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
An update of the immunization status should ideally be
performed before starting AZA/6-MP, as well as serologies for
Hepatitis B virus, Hepatitis C virus (HCV), varicella zoster virus
(VZV), and Epstein–Barr virus, as severe varicella and severe
primary infectious mononucleosis (some with hemophagocytic
lymphohistiocytosis), especially in young male patients, have
been recently reported.29,110 In accordance with ECCO guide-
lines,111 we propose that screening for HCV using antibody
testing should be considered and if positive, it should be con-
ﬁrmed by detection of HCV RNA because the potential risk of
worsening liver function as a result of immunosuppressive ther-
apy, concomitant infection with other viruses such as Hepatitis B
virus or HIV or by potentiating the effects of hepatotoxic medi-
cations. Immunomodulators may furthermore inﬂuence active
chronic HCV infection. Immunomodulators are not contra-
indicated but in our view should be used with caution after dis-
cussion with a hepatologist.
AZA-associated hemophagocytic lymphohistiocytosis is
a rare, but often fatal disease.29,110,112 Epstein–Barr virus IgG
screening should be also considered before the initiation of
immunomodulator therapy. In line with the ECCO guideline, we
advise anti-TNF-alpha monotherapy rather than thiopurines in
Epstein–Barr virus young seronegative patients.111
Nodular regenerative hyperplasia is a rare hepatic disorder
that may lead to severe portal hypertension. The risk of
developing nodular regenerative hyperplasia during AZA treat-
ment is low. However, it seems that male patients with previous
extensive ileal resection constitute a higher risk group.113
A recent retrospective study of the Danish population
database linked the development of cervical cancer to the
cumulative use of AZA.114 The increasing HPV prevalence
also seems to impact on the risk of oral cancer and dysplasia
in AZA-treated patients, based on an extensive literature
review.115 For that reason, in accordance with the ECCO
guideline, we recommend regular gynecological screening
for cervical cancer for women with IBD, especially if treated
with immunomodulators. Although current or past infection
with HPV is not a contraindication for immunomodulator
therapy, discontinuation of immunomodulator therapy should
be considered in patients with extensive cutaneous warts and/
or condylomata, as well as routine prophylactic HPV vaccina-
tion for females and males in accordance with national
guidelines.111
Question 6: Special Situations: Vaccination,
Surgery, Pregnancy, and Lactation
Patients treated with thiopurines should be considered
immunosuppressed, for that reason, the use of live vaccines is
contraindicated. In practice, immunizations with live vaccines
should be performed 1 month before initiation of thiopurines or
at least 3 months after discontinuation of these agents. Peptidic and
polysaccharidic vaccines can be administered safely during immu-
nosuppression with thiopurines, but the response may be impaired.
GRADE: moderate, recommendation: strong for all the
above recommendations.
Vaccination on AZA/6-MP.
should be considered as potentially immunosuppressed
despite the relatively low dose of medication used in the treatment
of IBD. In this patient population, there are 2 situations to discuss
separately: the use of live vaccines and the use of inactivated
vaccines, the latter further divided into the use of peptidic and
polysaccharidic vaccines.
The principle of live vaccines is to induce immunity by
causing a very mild form of the disease through the injection of an
attenuated form of the pathogenic agent to elicit a curing immune
reaction. Although severe vaccine-related illnesses after live
vaccines in immunosuppressed patients remains rare in the
literature, AZA has been involved in the development of severe
disease after the administration live polio and tuberculosis BCG
vaccines.116,117 Based on these cases, the use of live vaccines
during AZA and 6-MP therapy is strictly contraindicated.118
Live vaccines currently in use are the combined measles-
mumps-rubella, yellow fever, Ty21a oral typhoid, live attenuated
inﬂuenza vaccine, rotavirus, and Bacille Calmette Guerin (BCG)
vaccines. Caution should also be used when close contacts of
patients immunosuppressed by thiopurines are vaccinated with
live vaccines, as transmission of live vaccine particles may occur,
especially from diapers of infants vaccinated against rotavirus and
from skin lesions (if they occur) of subjects vaccinated against
varicella.118 However, according to US CDC guidelines, therapy
with #3.0 mg$kg21$d21 AZA or #1.5 mg$kg21$d21 6-MP are
not regarded as contraindications for the administration of the
zoster vaccine.119 It is thus recommended to perform vaccination
with live vaccines before the introduction of AZA or 6-MP, or
after a washout period of these immunosuppressors.118,120 In
practice, immunizations with live vaccines should be performed
1 month before the initiation of thiopurines or at least 3 months
after discontinuation of these agents if they were previously given
to the subject to be vaccinated.
Peptidic and polysaccharidic vaccines can be administered
safely during immunosuppression with thiopurines, but the
response may be impaired, especially for polysaccharidic vaccines
that do not elicit memory T cells and are less inﬂuenced by the
immunosuppression. Therefore, immune response is best elicited
if those vaccines are administered at least 1 month before the
initiation of the thiopurines therapy.111 Peptidic vaccine boosters,
however, can be administered efﬁciently during immunosuppres-
sion, as they rely on preexisting memory T cells.120,121 Therefore,
nonlive vaccines against tetanus, diphtheria, poliomyelitis, pertus-
sis, human papilloma virus (for both males and females), inﬂu-
enza, Pneumococcus (PCV 13 and PPSV 23) hepatitis B,
Haemophilus inﬂuenza, Meningococcus, and tick-borne encepha-
litis and others can be administered under AZA/6-MP (Table 2).
Surgery
Performing surgery under thiopurines therapy should be
discussed according to two different scenarios: IBD-related
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abdominal surgery and other surgical procedures, mostly outside
of the abdominal cavity.
Surgery is a common outcome for patients with CD and
concerns a minority of patients with UC, but these surgeries are
rarely performed early in the course of the disease.122,123 As
a result, a large subset of patients with IBD who become surgical
candidates are under immunosuppressors or anti–TNF-alpha
agents. Surgery for IBD-related indications (intestinal resections,
abscesses drainage, or colectomy) has not been associated with
increased risks of complications.21,31,124,125 Accordingly, the
recent ECCO consensus on surgery for UC states that preopera-
tive thiopurines do not increase the risk of postoperative compli-
cations.126 There is less evidence to describe the risk of
complications in immunosuppressed patients undergoing surgery
for IBD-unrelated reasons. Most of the literature refers to surgical
complications of orthopedic surgeries, in particular joint replace-
ments, in patients immunosuppressed for rheumatoid arthritis. In
this population, the risks of this type of surgery have not been
found to be increased by the concomitant administration of meth-
otrexate or AZA.31,127,128 However, as a high rate of infectious
complications has been reported in transplant recipients undergo-
ing joint replacement, patients under combination of immunosup-
pressors should be considered at high risk for surgery.129
Pregnancy and Lactation
AZA crosses the placental barrier, but its metabolization
seems reduced in the fetal liver, as 6-TG levels are reduced
(compared with the mother’s level) and 6-MMP not found in infant
red blood cells.130 There are multiples clinical series and a meta-
analysis to show that thiopurines can be safely administered through-
out conception and pregnancy.32,131–133 This position corresponds to
the ECCO consensus on reproduction in IBD.134 As a small amount
of AZA has been found in breast milk, the ECCO consensus rates as
“probably safe” AZA during lactation. The available evidence, how-
ever, shows no increased rate of infections or other complications in
babies breastfed by mothers taking AZA.23,135 With respect to the
extensive beneﬁcial effects of breastfeeding, lactation should be still
be encouraged in this situation.
CONCLUSION
AZA/6-MP have been used for decades in IBD, where they
represented the ﬁrst second-line therapy for unresponsive or
steroid-dependent patients. A role in postoperative prophylaxis in
CD was also recognized. These initial indications for thiopurines
have been progressively challenged by the introduction and wider
use of anti–TNF-alpha agents. The advent of biosimilars of the
anti–TNF-alpha is likely to even further challenge the established
indications of thiopurines. Furthermore, biological therapies with
novel mechanisms of actions, in particular antimigration antibod-
ies such as vedolizumab, are likely further to decrease our need
for thiopurines. Finally, retrospective and longitudinal analyses of
large cohorts have shown potential severe albeit rare adverse
effects of these products.
Despite all of these reasons to limit the use of thiopurines,
these drugs offer some advantages, in combination with anti–-
TNF-alpha drugs and in special situations, and may ﬁnd a renewed
role as maintenance therapy after MMX-budesonide use in UC. It
thus remains useful to master their application, which has become
more sophisticated in line with more ambitious treatment goals for
the beneﬁt of patients with IBD.
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